Document Detail


Amiodarone induced hyperthyroidism: a case series and brief review of literature.
MedLine Citation:
PMID:  8946449     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To delineate the incidence, clinical features, diagnosis, and treatment options for amiodarone induced hyperthyroidism (AIH), we reviewed the medical records of ten patients with AIH. Eight of these 10 patients were detected on initial review of the records of 200 patients in treatment with amiodarone, and the other 2 following notification by their endocrinologists. AIH occurred in 4.2% of patients being treated with amiodarone. At the time of diagnosis of AIH, the mean (SD) values for age, duration of treatment with amiodarone, and dose of amiodarone were 62.9 (8.96) years, 38.3 (20) months, and 366.7 (122) mg/day, respectively. The most common clinical features were weight loss and goiter (each seen in 90% of patients). Serum thyroxine (T4), triiodothyronine, and free thyroxine index (FTI) showed an increase of 84%, 47%, and 110%, while thyroid stimulating hormone (TSH) and resin T4 uptake decreased 96% and 14%, respectively, from previous values. The most consistent laboratory findings, seen in all patients, were subnormal TSH and abnormally high FTI. One patient required no treatment; another underwent prompt total thyroidectomy. The other eight were treated medically; two of them underwent total thyroidectomy later, for medical failure or adverse effects. Amiodarone was continued in four patients. The most commonly used antithyroid medication was propylthiouracil. AIH presents in the early or late phases of treatment with amiodarone with typical clinical features of a hyperthyroid state, fall in TSH, and increase in FTI. Antithyroid medications are reasonably effective in the management of AIH.
Authors:
K J Harjai; A A Licata
Related Documents :
2583879 - A critical theory of medical discourse: how patients and health professionals deal with...
19028749 - Role of medication in the level of aluminium in the blood of chronic haemodialysis pati...
2527899 - Implications of the changing medical profile of a dental school patient population.
19593139 - Low-molecular-weight heparin for thromboprophylaxis.
20450239 - Implications of opioid analgesia for medically complicated patients.
12419979 - Venous thromboprophylaxis in acutely ill patients: nursing role.
2238449 - Fatal poisoning by rumex crispus (curled dock): pathological findings and application o...
19843649 - Cerebellar agenesis revisited.
672699 - Introducing instructional objectives in indonesian medical schools.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Pacing and clinical electrophysiology : PACE     Volume:  19     ISSN:  0147-8389     ISO Abbreviation:  Pacing Clin Electrophysiol     Publication Date:  1996 Nov 
Date Detail:
Created Date:  1997-04-08     Completed Date:  1997-04-08     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  7803944     Medline TA:  Pacing Clin Electrophysiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1548-54     Citation Subset:  IM    
Affiliation:
Department of Medicine, Cleveland Clinic Foundation, Ohio, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amiodarone / administration & dosage,  adverse effects*
Female
Goiter / chemically induced
Humans
Hyperthyroidism / chemically induced*,  diagnosis,  therapy
Male
Middle Aged
Thyroid Hormones / blood
Time Factors
Weight Loss / drug effects
Chemical
Reg. No./Substance:
0/Thyroid Hormones; 1951-25-3/Amiodarone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Improved nonthoracotomy defibrillation based on ventricular fibrillation waveform characteristics.
Next Document:  Quality-of-life in patients receiving implantable cardioverter defibrillators at or before age 40.